Asahi Kasei Pharma

4:00 PM - 4:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 104C
The Asahi Kasei Group operates in the three business sectors of Material, Homes, and Health Care with $20B net revenue. In Healthcare segment, Asahi Kasei group has two pharmaceutical companies, named Asahi Kasei Pharma (AKP) and Veloxis. AKP is a mid-sized R&D-based Japanese company with strong presence in autoimmune, musculoskeletal, critical care and infectious diseases fields established through R&D and commercialization of our products, Teribone, Recomodulin, Kevzara, Plaquenil, Cresemba, etc. Veloxis is an US based company leading transplant area with an innovative product, Envarsus XR and ongoing development activities in that space. AKP and Veloxis have an ambition to become one global specialty pharma to serve for our patients in immunology and transplant-related areas. For our future growth and to achieve our mission, we are collaborating closely and actively looking for opportunities from early to late stage in-licensing with global rights as well as M&A.
Company Type:
Publicly Traded Company
Company HQ State:
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Multiple Products in Market
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Board Director, Vice-Presidential Executive Officer
Asahi Kasei Pharma